As the number of lives affected by the COVID-19 pandemic in the world is still high, the health and safety of our congress attendees remains our primary concern. The pandemic changed almost everything. During the last year we have learned a lot about virtual communication as well as found some advantages of on-line meetings, almost all congresses were virtual. In the same time, I believe we all would be happy to meet each other face-to-face. Although, it is an indisputable fact that an on-site congress is not possible. Despite the raising vaccination rate against COVID-19 the morbidity is still high as well as the travelling and gathering restrictions imposed by the participating countries are present.
Bearing in mind this situation, the XXI Nordic Stroke Society Congress will be virtually held on the August 26-27, 2021.
The aim of the Nordic Stroke Society is to gather all medical professionals working in the field of stroke from the Nordic and Baltic countries, to share in their experience, learn from the best experts in the field and grow their professional network. So, we and our technical team, will utilise the top most technical solutions to provide the participants with the virtual experience as comfortable and rewarding as possible.
In order to make participation affordable to everybody, The Nordic Stroke Society is offering a modest fee for the virtual congress. We look forward to welcome you to the XXI Nordic Stroke Society Congress!
On behalf of Organising and Scientific Committees
Assoc. Prof. Evija Miglane
Head of Latvian Stroke Society
Head of Latvian Society of Neurologists
|Description||In all materials mentioned seperatelly as General partner In all materials logo is bigger than other partner's logo ( 1/1)||In all materials mentioned together with other Partners. Logo size and dimensions comparing to General partner 1/2.||In materials mentioned in supporter section Logo size and dimensions comparing to General partner 1/4.|
|Landing page||Logo and information in sponsor page||x||x||x|
|Logo and information in sponsor page||x||x||x|
|Logo in sliding line||x||x|
|Studio||Logo in screens||x||x||x|
|Livestream||Live stream countdown||x||x||x|
|Picture in picture view logo||x||x|
|Logo in good bye pic||x||x||x|
Full hall view branding
|2 X 30 min general session||1 x 30 min parallel session|
|EUR 20 000||EUR 15 000||EUR 5 000|
|10 particapant tickets||5 particapant tickets|
ACCREDITATION STATEMENT AND CREDIT DESIGNATION
European Accreditation Council for Continuing Medical Education (UEMS/EACCME)
The XXI Nordic Stroke Congress, Riga, Latvia, 26/08/2021-27/08/2021 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 15 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
American Medical Association (AMA)
Through an agreement between the Union Européenne des Médecins Spécialistes and the American
Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA
Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be
Each participant can only receive the number of credits he/she is entitled to according to his/her
actual participation at the event.
In order to help you issue individual certificates to each participants, please find below the
breakdown of ECMEC®s per day:
26.08.2021 - 8.00
27.08.2021 - 7.00
The EACCME® awards ECMEC®s on the basis of 1 ECMEC® for one hour of CME with a maximum of 8
ECMEC®s per day. Cf. Chapter X of UEMS 2016.20.
After attending this event, participants should be able to:
Address individual needs of their own continuous professional development plan.
Discuss the most recent advances and knowledge in all aspects of stroke including about the different types of stroke, best practice in their current treatment, prevention and rehabilitation
Discuss updates about the epidemiology, risk factors and mechanistic causes of different types of stroke
Identify new and emerging treatments and approaches to prevention
Describe common consequences of stroke such as cognitive decline and dementia and how these may be prevented.
TO RECEIVE YOUR CME/CPD CERTIFICATE
The CME/CPD certificate will be available after completing the online evaluation and credit claiming procedure. The process takes about 5 minutes. After the event you will receive evaluation survay in your e-mail.
We thank you for your feedback as it is an important part of CME/CPD accreditation and helps improve future educational offerings.
till 28 June 2021
from 28 June till event day
|Doctors||EUR 80||EUR 100|
|Other visitors||EUR 50||EUR 70|
|Speakers||If want to become Stroke Society member||Present|
|Baltic states - EUR 10||0|
|Nordic states - EUR 20|
Participation fee include:
XXI Nordic Stroke Society Congress virtual meeting will offer you a full virtual experience and the opportunity to take part in every aspect of the programme including:
Payment of registration fees (in Euro) can be made as follows:
For group registration (10 participants and more) please contact: email@example.com
XXI Nordic Stroke Congress Organizer:
LTD „MRVLS” Address: Ģertrūdes street 66, Rīga, LV-1009
Director of the event : Mārtiņš Ikaunieks
Phone number: + 371 29352642
The Angels Initiative, a non-promotional, health care project of Boehringer Ingelheim, in partnership with the European Stroke Organisation (ESO) and the World Stroke Organisation (WSO), aims to improve acute stroke care around the world. The initiative has two goals: to increase the number of stroke ready hospitals so that more patients have access to the specialized care they need and to optimise the quality of treatment in existing stroke centres.
Our mission is to build a stroke community across the world to improve acute stroke networks, treatment procedures and share knowledge.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. From research to laboratory tests to personalized healthcare Roche touches the entire spectrum of diagnostic users. Today, Roche has a portfolio that tackles the full cycle of healthcare under one roof: prevention, diagnosis, treatment and monitoring of disease.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. For more information, go to www.bayer.com.
A global pharmaceutical Group governed by a non-profit Foundation, with headquarters in Suresnes, France. Since opening the first laboratory in 1954, Servier have been committed to therapeutic progress to serve patient needs with the help of healthcare professionals. Servier strive to transmit to future generations a world that can ensure access to quality health care for all.